The Effects of Anemia and Blood Transfusion on Patients With Stage III-IV Ovarian Cancer

Altman, Alon D.; Liu, Xiao Qing; Nelson, Gregg; Chu, Pamela; Nation, Jill; Ghatage, Prafull

doi:10.1097/igc.0b013e3182a57ff6

Cited by 25 publications

(16 citation statements)

References 49 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low hemoglobin is common in oncological diseases, including in lung (16,17), breast (17), gastric (18) and ovarian cancer (19). There is evidence for a correlation between hemoglobin levels and the prognosis of patients with NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer

Zhang

et al. 2018

mol clin onc

View full text Add to dashboard Cite

To date, few studies have reported the prognostic value of pre-treatment hemoglobin levels in patients with non-small cell lung cancer (NSCLC). In the present study, 416 patients with NSCLC were retrospectively reviewed. Univariate Cox proportional hazards regression analysis demonstrated that patients with normal pre-treatment hemoglobin (NPHb) levels had a greater chance of surviving for longer period, than did patients with low pre-treatment hemoglobin (LPHb) levels (HR, 2.05; 95% CI, 1.63-2.57; P<0.001). After adjustment for age, sex, tumor-node-metastasis stage, Karnofsky performance status, lung lobectomy, chemotherapy and radiotherapy, multivariate Cox proportional hazards regression analysis revealed that LPHb was an independent predictor for the poor prognosis of patients with NSCLC (HR, 1.86; 95% CI, 1.47-2.36; P<0.001). Estimation of the cumulative survival revealed that the overall survival of NPHb patients was significantly higher than that for LBHb patients (P<0.05), independent of whether the patients had received lung lobectomy or chemotherapy treatments. In conclusion, low pre-treatment hemoglobin levels were demonstrated to be an independent biomarker for poor prognosis in patients with NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer

Zhang

et al. 2018

mol clin onc

View full text Add to dashboard Cite

show abstract

“…[3, 4] Numerous studies have demonstrated that anemia is a prognostic indicator of poor clinical and oncologic outcomes. [5–10]…”

Section: Introductionmentioning

confidence: 99%

How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology

Prescott

Taylor

López-Olivo

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

Background Most non-oncologic clinical practice guidelines recommend restrictive allogeneic blood transfusion practices; however, there is a lack of consensus regarding the best transfusion practice in oncology. We conducted a systematic review of the literature to compare the efficacy and safety of restrictive versus liberal transfusion strategies in patients with cancer. Methods A literature search using MEDLINE, PUBMED and EMBASE identified all controlled studies comparing the use of restrictive with liberal transfusion in adult oncology participants up to August 10, 2015. Two review authors independently assessed studies for inclusion, extracted data and appraised the quality of the included studies. The primary outcomes of interest were blood utilization and all-cause mortality. Results Out of 4241 citations, six studies (3 randomized and 3 non-randomized) involving a total of 983 patients were included in the final review. The clinical context of the studies varied with 3 chemotherapy and 3 surgical studies. The overall risk of bias in all studies was moderate to high. Restrictive transfusion strategies were associated with a 36% reduced risk of receiving a perioperative transfusion (risk ratio (RR) 0.64, 95% confidence interval (CI) 0.49 to 0.83). There was no difference in mortality between the strategies (RR 1.00, 95% CI 0.32 to 3.18). There were no differences in adverse events reported between the restrictive and liberal transfusion strategies. Conclusion Restrictive strategy appears to decrease blood utilization without increasing morbidity or mortality in oncology. This review is limited by a paucity of high quality studies on this topic. Better designed studies are warranted.

show abstract

“…In this investigation, we demonstrate that implementation of standardized blood transfusion practices, an intraoperative hemostasis checklist, enhancedintraoperative fluid status communication, and evidence-based use of tranexamic acid was associated with reduced blood loss and red blood cell transfusion rates for patients undergoing laparotomy for ovarian or advanced endometrial cancer. This reduction is clinically important, given that perioperative blood transfusion carries well-described risks and negative outcomes (16, 25). While a bundled approach focused on reducing blood transfusion in gynecologic oncology patients has not been previously reported, our findings are consistent with those published in previous studies showing the efficacy of tranexamic acid and standardized blood transfusion guidelines (7, 13).…”

Section: Discussionmentioning

confidence: 99%

Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy

Wallace

Halverson

Jankowski

et al. 2018

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

The Effects of Anemia and Blood Transfusion on Patients With Stage III-IV Ovarian Cancer

Cited by 25 publications

References 49 publications

Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer

Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer

How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology

Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy

Contact Info

Product

Resources

About